Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Soleno Therapeutics, Inc. is one of them.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for being one of the most oversold stocks. It is a clinical-stage biotech focused on rare diseases and has seen significant stock volatility in 2025 following the commercial launch of its lead product, VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS). The therapy addresses extreme hunger and metabolic challenges in PWS patients and represents a key step in the company’s rare disease portfolio.

The stock experienced a sharp decline in mid-August after a short-seller report raised safety concerns about VYKAT XR, triggering a selloff of over 10% in two trading days and a subsequent securities class action investigation. Despite this, the drug has gained early traction, with 646 patient initiations from 295 prescribers covering more than 100 million U.S. lives. Soleno Therapeutics, Inc. (NASDAQ:SLNO) is also pursuing European approval through the EMA, signaling its strategy for international market expansion.

Market reaction has left the business among the most oversold healthcare stocks of 2025, with the stock losing roughly 26% in a month. However, technical indicators suggest the selling pressure may be nearing exhaustion. Analysts remain optimistic, maintaining buy ratings with average price targets of $110–$120, reflecting confidence in the firm’s long-term commercial potential.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) continues to focus on raising awareness of VYKAT XR through clinical data presentations and targeted commercialization efforts, aiming to secure a solid foothold in the PWS treatment market despite short-term headwinds.

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.